Cancer combo trial pulled before it even started
NCT ID NCT07511972
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This was a phase 2 study planned to test a new drug called NGM707 combined with the immunotherapy pembrolizumab in people with advanced or metastatic solid tumors, specifically colorectal cancer. The goal was to see if the combination could shrink tumors and to check for side effects. However, the study was withdrawn before any participants were enrolled, so no results are available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
NGM707 plus pembrolizumab
What this could lead to
If it worked, this combination could shrink tumors or slow cancer growth in people with advanced solid tumors that have not responded to other treatments.
What could go wrong
This trial was withdrawn before enrolling any participants, so there is no data on safety or effectiveness. The combination may cause side effects or fail to work better than existing options.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CRC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.